Recent Updates

February 2020

Community-acquired pneumonia - management in the community: Following publication of NICE NG138 the formulary guidance has been updated. Click here for information

Budesonide rectal foam has been added to the formulary as an amber (specialist) option for the management of ulcerative colitis. Click here for place in therapy for budesonide rectal foam

Thealoz Duo (sodium hyaluronate 0.15% / trehalose 3%) eye drops have been added to the formulary as an amber (specialist) option for severe dry eye. Click here for place in therapy for Thealoz Duo eye drops

Liothyronine: GPs who receive a request from a consultant to prescribe liothyronine for a patient who has not previously received liothyronine should contact the CCG Medicines Optimisation team before accepting the request. Click here

Specialised Medicines Service prescribing guidelines have been agreed for flupentixol decanoate, haloperidol decanoate, and zuclopenthixol decanoate depot injections. The guidelines only apply to patients under the care of DPT, for patients under the care of Livewell Southwest, prescribing and monitoring remains with the trust. The formulary entries have been updated with a link to the guidelines

January 2020

New European Medicines Agency safety alert for ingenol mebutate gel issued January 2020. Healthcare professional letter expected week beginning 27th January 2020.

December 2019

DermisPlus Prevent pressure redistribution devices have been added as green (first line) options to help reduce the risk of pressure damage as part of a pressure ulcer prevention strategy. Click here for more information.

  • KerraPro Pads have been removed from the formulary

UCS Debridement single-use pre-moistened debridement cloths 20cm x 20cm have been added as green (first line) options for soft mechanical debridement of wounds. Click here for more information.

  • Debrisoft debridement pads 10cm x 10cm have been reclassified as amber (specialist) options for debridement of diabetic foot ulcers only.

Acticoat 5cm x 5cm, 10cm x 10cm, 10cm x 20cm, 20cm x 40cm have been reclassified as amber (specialist) options for partial and full-thickness wounds with signs of local infection.

UrgoClean Ag dressings 6cm x 6cm, 10cm x 10cm, 15cm x 20cm have been added as amber (specialist) options for when infected wound sites require debridement. Click here for more information on Acticoat and UrgoClean Ag.

Fluphenazine decanoate (Modecate) injections have been removed from the formulary following product discontinuation (due to manufacturing and supply problems not any safety issues). Any remaining patients currently prescribed these products should be referred to specialist services for consideration of alternative therapy (DPT have confirmed that referral should be via the assessment teams as normal).

Acute cough guidance review: Following publication of NICE NG120 Cough (acute): antimicrobial prescribing (February 2019), formulary guidance has been revised and updated. Please see the formulary for further guidance.

Chronic Obstructive Pulmonary Disorder (COPD) guidance review: Following publication of updated guidance from both GOLD and NICE in 2019, formulary guidance on the management of COPD has been revised and updated. The review incorporates management of stable COPD and COPD exacerbations and includes new antimicrobial guidance for acute exacerbations. Please see the formulary for further guidance.

The environmental impact of inhalers: New guidance has been produced which highlights the carbon footprint of inhalers, and steps that may be taken to mitigate environmental impact in terms of inhaler device choice, waste and recycling. Please see the formulary for further guidance

Community-acquired Pneumonia (CAP) guidance review: Following publication of NICE NG138 Pneumonia (community-acquired): antimicrobial prescribing (September 2019), formulary guidance was discussed and will be updated soon, further details will be circulated at that time.

Chapter 14. Immunological products and vaccines: The chapter has undergone format changes and information has been consolidated to streamline the accessibility of clinically appropriate guidance and treatment options. Vaccination strengths, doses, and treatment regimens have been removed and replaced with a permanent link to Public Health England's 'The Green Book'. Please see the formulary for further guidance.

Chlamydia trachomatis: Following an update to the Chlamydia trachomatis guideline from the British Association for Sexual Health and HIV (BASHH), formulary guidance has been reviewed and updated. Please see the formulary for further information.

Chapter 17. Wound Management Formulary: The chapter has undergone format changes and information has been consolidated to streamline the accessibility of clinically appropriate guidance and treatment options. Please see the formulary for further guidance.

November 2019

User improvements: *NEW* Search Functionality

Following feedback from the user survey, a new improved search function has been added which allows users to filter search results by Formulary or Referral pages.

October 2019

Learning: *NEW Multiple Choice Quizzes for 2019*

New and updated multiple choice quizzes (MCQs) have been added to the formulary. The quizzes are designed to highlight key areas of formulary guidance and to help keep up-to-date with national and local guidance. Click here for more information. The following quizzes are new or have been updated:

  • Asthma (NEW)
  • Epilepsy (UPDATED)
  • Pain and analgesia (NEW)
  • Parkinson's Disease (NEW)

Estriol intravaginal cream 0.01% has been removed from the formulary in favour of estriol intravaginal cream 0.1%. Click here for more information.

GlucoRx CarePoint Ultra pen needles 4mm/32G have been added to the formulary as green (first line) options. Click here for more information.

Kelhale Aerosol inhalation metered dose inhalers (beclometasone dipropionate [BDP] extrafine) 50micrograms and 100micrograms have been added to the formulary as green (first line) options. BDP inhalers should be prescribed by brand since they are not all interchangeable. Click here for more information.

  • The following products have been reclassified as blue (second line) options:
    • Qvar Aerosol inhalation metered dose inhalers (BDP) 50micrograms and 100micrograms
    • Qvar Autohaler breath-actuated aerosol inhalation metered dose inhalers (BDP) 50micrograms and 100micrograms
    • Qvar Easi-breathe breath-actuated aerosol inhalation metered dose inhalers (BDP) 50micrograms and 100micrograms

The following changes have been made to formulary recommendations on bisphosphonates:

  • Ibandronic acid tablets 150mg have been reclassified as a blue (second line) option for the treatment of postmenopausal osteoporosis.
  • Risedronate sodium tablets 5mg, 30mg, and weekly tablets 35mg have been reclassified as a blue (second line) option for the treatment of osteoporosis
  • Click here for more information

Espranor (buprenorphine) oral lyophilisates 2mg and 8mg have been added to the formulary as an amber (specialist) option as substitution treatment for opioid drug dependence. Espranor is not interchangeable with other buprenorphine products, as the bioavailability of products differ.

Latanoprost / timolol single unit dose eye drops (preservative-free) 50micrograms / 5mg/ml have been added to the formulary as an amber (specialist) option. Click here for more information.

Following ongoing long-term supply issues and discontinuation of some branded nifedipine, the formulary entry has been updated to provide prescribers with supporting information. Click here for more information.

Pencillamine has been reclassified as red (hospital only)

Chapter 18. Continence Formulary: The chapter has undergone format changes and information has been consolidated to streamline the accessibility of clinically appropriate guidance and associated appliances. Please see the formulary for further guidance and recommended appliances.

Psoriasis management: Following updates to NICE Guideline CG153 Psoriasis: assessment and management (September 2017) and British Association of Dermatologists (BAD) Clinical Guideline: Psoriasis (October 2018). Formulary guidance has been extensively revised and updated. Please see the formulary for further guidance.

Commissioning Policy: The routine commissioning of glycopyrronium bromide oral solution is accepted in Devon for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders (see Commissioning Policy for more details). Different formulations of glycopyrronium oral solution are not bioequivalent and so should be prescribed by brand. Sialanar is the recommended brand. Click here for more information

Commissioning Policy: The routine commissioning of Continuous Glucose Monitors (CGMs) is accepted in Devon for patients with type 1 diabetes mellitus in line with specific criteria (see Commissioning Policy for more details). Click here for more information

Following agreement of the Dapsone Specialised Medicines Service prescribing guideline, the formulary entry has been updated with a link to the guideline.

Last updated: 19-02-2020

 

Home > Formulary > Updates > Recent Updates

 

  • First line
  • Second line
  • Specialist
  • Hospital